Valneva was awarded a tropical illness PRV in November 2023 after it developed Ixchiq, its single-dose vaccine for the prevention of the illness attributable to the chikungunya virus, the corporate mentioned.
Ixchiq was the primary preventive shot to be permitted in the USA for the mosquito-borne illness.
The chikungunya virus spreads to folks by means of the chunk of an contaminated mosquito. The commonest signs are fever and joint ache. Different signs could embrace headache, muscle ache, joint swelling or a rash.
The FDA’s tropical illness precedence evaluation voucher program is meant to encourage the event of recent medication for the prevention and remedy of tropical ailments. The vouchers shorten the evaluation time of a brand new drug by by 4 months, from 10 months to 6; the customer can apply it to a product they’re growing.
“As proven with the current approval of our chikungunya vaccine, we stay dedicated to rising our portfolio of vaccines addressing unmet medical wants which have the potential to rework folks’s lives,” Valneva’s chief govt officer, Thomas Lingelbach, mentioned in a information launch.
The French firm mentioned it will make investments proceeds from the sale into analysis and improvement tasks, together with the co-development of its Part 3 vaccine candidate in opposition to Lyme illness and extra scientific trials for IXCHIQ.